IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives.
CAPS
FMF
IL-1
TRAPS
anakinra
canakinumab
rilonacept
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
10
2020
accepted:
14
12
2020
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
23
6
2021
Statut:
epublish
Résumé
Autoinflammatory diseases (AIDs) represent a rare and heterogeneous group of disorders characterized by recurrent episodes of inflammation and a broad range of clinical manifestations. The most common symptoms involve recurrent fevers, musculoskeletal symptoms, and serositis; however, AIDs can also lead to life-threatening complications, such as macrophage activation syndrome (MAS) and systemic AA amyloidosis. Typical monogenic periodic fever syndromes include cryopyrin-associated periodic fever syndrome (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency/hyper IgD syndrome (MKD/HIDS), and familial Mediterranean fever (FMF). However, a number of other clinical entities, such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), Kawasaki disease (KD) and idiopathic recurrent pericarditis (IRP), display similar phenotypical and immunological features to AIDs. All these diseases are pathophysiologicaly characterized by dysregulation of the innate immune system and the central pathogenic role is attributed to the IL-1 cytokine family (IL-1α, IL-1β, IL-1Ra, IL-18, IL-36Ra, IL-36α, IL-37, IL-36β, IL-36g, IL-38, and IL-33). Therefore, reasonable therapeutic approaches aim to inhibit these cytokines and their pathways. To date, several anti-IL-1 therapies have evolved. Each drug differs in structure, mechanism of action, efficacy for the treatment of selected diseases, and side effects. Most of the available data regarding the efficacy and safety of IL-1 inhibitors are related to anakinra, canakinumab, and rilonacept. Other promising therapeutics, such as gevokizumab, tadekinig alfa, and tranilast are currently undergoing clinical trials. In this review, we provide sophisticated and up-to-date insight into the therapeutic uses of different IL-1 inhibitors in monogenic periodic fever syndromes.
Identifiants
pubmed: 33603750
doi: 10.3389/fimmu.2020.619257
pmc: PMC7884884
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Interleukin-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
619257Informations de copyright
Copyright © 2021 Malcova, Strizova, Milota, Striz, Sediva, Cebecauerova and Horvath.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arthritis Rheum. 2012 Jul;64(7):2375-86
pubmed: 22294344
Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):141-9
pubmed: 23899820
Arthritis Rheumatol. 2014 Nov;66(11):3241-3
pubmed: 25049046
Turk J Pediatr. 2020;62(2):167-174
pubmed: 32419407
Arthritis Rheum. 2010 Jan;62(1):258-67
pubmed: 20039428
Genes Immun. 2020 Aug;21(4):211-223
pubmed: 32681062
Mod Rheumatol. 2015 Jul;25(4):621-4
pubmed: 25528863
Clin Rheumatol. 2014 Sep;33(9):1197-207
pubmed: 24935411
Front Immunol. 2019 Nov 01;10:2578
pubmed: 31736980
Ann Rheum Dis. 2020 Oct;79(10):1362-1369
pubmed: 32571870
Rheumatology (Oxford). 2020 Oct 1;59(10):2711-2724
pubmed: 32533192
Arthritis Rheum. 2008 Aug;58(8):2443-52
pubmed: 18668535
Ann Rheum Dis. 2015 Sep;74(9):1714-9
pubmed: 24906637
Arthritis Rheum. 2008 May;58(5):1516-20
pubmed: 18438813
Clin Rheumatol. 2017 Aug;36(8):1707-1713
pubmed: 28624931
Nat Genet. 1999 Jun;22(2):175-7
pubmed: 10369261
Rheumatology (Oxford). 2012 Oct;51(10):1855-9
pubmed: 22740624
Rheumatol Int. 2015 Oct;35(10):1733-7
pubmed: 26001859
J Clin Pharm Ther. 2015 Dec;40(6):620-5
pubmed: 26547265
Medicine (Baltimore). 2008 Nov;87(6):301-310
pubmed: 19011501
N Engl J Med. 2006 Aug 10;355(6):581-92
pubmed: 16899778
N Engl J Med. 2018 May 17;378(20):1908-1919
pubmed: 29768139
Int J Rheum Dis. 2020 Jul;23(7):977-981
pubmed: 32558310
Arthritis Res Ther. 2013;15(3):R64
pubmed: 23718630
Arthritis Res Ther. 2015 Sep 04;17:243
pubmed: 26337145
Arthritis Rheum. 2008 Mar;58(3):864-8
pubmed: 18311804
Arthritis Rheum. 2008 Aug;58(8):2432-42
pubmed: 18668591
Arthritis Rheum. 2001 Jun;44(6):1416-9
pubmed: 11407703
Lancet Rheumatol. 2020 May;2(5):e270-e280
pubmed: 33005902
MAbs. 2011 Jan-Feb;3(1):49-60
pubmed: 21048425
Int J Mol Sci. 2018 Sep 11;19(9):
pubmed: 30208640
Immunol Rev. 2018 Jan;281(1):8-27
pubmed: 29247995
Arthritis Res Ther. 2011 Feb 28;13(1):R34
pubmed: 21356079
Rheumatology (Oxford). 2016 Aug;55(8):1499-506
pubmed: 27143789
Pediatr Nephrol. 2007 Sep;22(9):1391-4
pubmed: 17486372
N Engl J Med. 2009 Jun 4;360(23):2416-25
pubmed: 19494217
Ann Rheum Dis. 2017 Jan;76(1):173-178
pubmed: 27269295
Arthritis Res Ther. 2011;13(6):R202
pubmed: 22152723
Arthritis Rheumatol. 2016 Nov;68(11):2795-2805
pubmed: 27213830
Pediatr Clin North Am. 2018 Aug;65(4):691-709
pubmed: 30031494
N Engl J Med. 2003 Jun 19;348(25):2583-4
pubmed: 12815153
Ann Rheum Dis. 2019 Aug;78(8):1025-1032
pubmed: 31018962
Int J Rheum Dis. 2015 May;18(4):473-5
pubmed: 25522898
Clin Rheumatol. 2016 Feb;35(2):441-6
pubmed: 25213327
Autoimmun Rev. 2016 Sep;15(9):931-4
pubmed: 27392503
Autoimmun Rev. 2012 Nov;12(1):14-7
pubmed: 22878269
Rheumatology (Oxford). 2007 Mar;46(3):473-8
pubmed: 16920754
Ann Rheum Dis. 2013 May;72(5):678-85
pubmed: 22753383
Int J Cardiol. 2020 Jul 15;311:77-82
pubmed: 32312616
Arthritis Rheumatol. 2017 Apr;69(4):854-862
pubmed: 27860460
Presse Med. 2019 Feb;48(1 Pt 2):e25-e48
pubmed: 30686513
Clin Rheumatol. 2015 Apr;34(4):807-9
pubmed: 24609716
Rheumatology (Oxford). 2020 Nov 1;59(11):3324-3329
pubmed: 32306038
J Otolaryngol Head Neck Surg. 2018 Jan 30;47(1):9
pubmed: 29382382
Clin Rheumatol. 2015 Jan;34(1):17-28
pubmed: 24953660
Ann Rheum Dis. 2011 Dec;70(12):2095-102
pubmed: 21859692
Open Access Rheumatol. 2017 Jul 11;9:123-129
pubmed: 28744167
Blood. 2011 Apr 7;117(14):3720-32
pubmed: 21304099
Orphanet J Rare Dis. 2016 Dec 7;11(1):167
pubmed: 27927236
J Rheumatol. 2017 Jan;44(1):102-109
pubmed: 28042127
Clin Sci (Lond). 2017 Aug 10;131(17):2241-2256
pubmed: 28798075
Intern Emerg Med. 2016 Sep;11(6):781-91
pubmed: 27221072
Rheumatology (Oxford). 2008 Mar;47(3):309-10
pubmed: 18174231
Arthritis Rheumatol. 2017 Aug;69(8):1679-1688
pubmed: 28482144
Ann Intern Med. 2012 Oct 16;157(8):533-41
pubmed: 23070486
EMBO Mol Med. 2018 Apr;10(4):
pubmed: 29531021
Clin Rheumatol. 2015 Sep;34(9):1503-11
pubmed: 25761640
Mod Rheumatol. 2020 Jan;30(1):166-171
pubmed: 30556769
Arthritis Care Res (Hoboken). 2014 May;66(5):765-72
pubmed: 24127202
Curr Cardiol Rep. 2020 Jun 19;22(8):59
pubmed: 32562029
Ann Rheum Dis. 2015 Sep;74(9):1636-44
pubmed: 26109736
Orphanet J Rare Dis. 2019 Oct 15;14(1):224
pubmed: 31615541
Autoimmun Rev. 2015 Feb;14(2):90-7
pubmed: 25308531
Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):827-36
pubmed: 22230390
Ann Rheum Dis. 2011 Dec;70(12):2155-8
pubmed: 21859689
J Allergy Clin Immunol. 2001 Oct;108(4):615-20
pubmed: 11590390
B-ENT. 2013;9(2):161-3
pubmed: 23909124
Inflammation. 2015 Feb;38(1):27-31
pubmed: 25139580
Mod Rheumatol. 2017 Mar;27(2):350-355
pubmed: 27328763
Semin Arthritis Rheum. 2017 Oct;47(2):295-302
pubmed: 28757235
Rheumatology (Oxford). 2016 Apr;55(4):669-79
pubmed: 26628580
Rheumatol Int. 2011 Nov;31(11):1409-17
pubmed: 21800117
J Leukoc Biol. 2020 Sep;108(3):937-952
pubmed: 32745339
Rheumatol Int. 2001 May;20(4):145-8
pubmed: 11411958
Nat Rev Rheumatol. 2019 Oct;15(10):612-632
pubmed: 31515542
Ann Rheum Dis. 2016 Apr;75(4):644-51
pubmed: 26802180
Arthritis Rheum. 2011 Mar;63(3):840-9
pubmed: 21360513
Semin Arthritis Rheum. 2017 Aug;47(1):115-120
pubmed: 28413100
Ann Rheum Dis. 2018 Jun;77(6):840-847
pubmed: 29472362
Mod Rheumatol. 2019 Jan;29(1):181-187
pubmed: 29451047